Stock Traders Buy Large Volume of Call Options on Microbot Medical (NASDAQ:MBOT)

Microbot Medical Inc. (NASDAQ:MBOT) was the recipient of unusually large options trading activity on Monday. Stock investors purchased 2,704 call options on the company. This is an increase of approximately 122% compared to the average volume of 1,216 call options.

Institutional Trading of Microbot Medical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC acquired a new position in Microbot Medical during the fourth quarter valued at $118,000. Goldman Sachs Group Inc. acquired a new stake in shares of Microbot Medical during the 1st quarter valued at about $57,000. Virtu Financial LLC purchased a new position in shares of Microbot Medical in the 1st quarter valued at about $42,000. Finally, Geode Capital Management LLC raised its holdings in Microbot Medical by 7.9% in the 4th quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company’s stock worth $160,000 after purchasing an additional 10,442 shares during the period. Institutional investors and hedge funds own 16.30% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $9.00 target price on shares of Microbot Medical in a research note on Thursday, April 10th.

Microbot Medical Stock Performance

MBOT stock traded down $0.47 on Monday, hitting $2.35. 3,871,718 shares of the company’s stock were exchanged, compared to its average volume of 1,709,578. The firm has a 50 day moving average price of $2.36 and a two-hundred day moving average price of $1.82. Microbot Medical has a 12-month low of $0.82 and a 12-month high of $3.38. The stock has a market cap of $85.31 million, a P/E ratio of -2.92 and a beta of 1.14.

Microbot Medical (NASDAQ:MBOT) last issued its quarterly earnings results on Wednesday, May 21st. The biotechnology company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.07. Sell-side analysts expect that Microbot Medical will post -0.71 earnings per share for the current fiscal year.

Microbot Medical Company Profile

Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.